At RSNA 2009, Agfa HealthCare executives highlighted opportunities that could come from a pending deal to acquire a German developer and producer of generic contrast media.
At RSNA 2009, Agfa HealthCare executives highlighted opportunities that could come from a pending deal to acquire a German developer and producer of generic contrast media. Dirk Debusscher, vice president of Agfa’s imaging division, described the bid for Insight Agents as a strategic step toward future growth. Insight’s contrast media will be distributed through the company’s extensive logistics and distribution network, Debusscher said, if the deal goes through. The company last week signed an agreement with Curagita Holding to acquire all the shares of its subsidiary Insight Agents, which includes the MR contrast agent Magnegita (gadopentetate dimeglumine), a generic form of Magnevist, and Iopamigita (iopamidol), a generic form of Isovue among its products.
